Nuvilex 3/18/2024 Earnings Report

Nuvilex EPS Results

• Actual EPS: -$0.65
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Nuvilex Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Nuvilex Announcement Details

• Date: 3/18/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Nuvilex (NASDAQ:PMCB), Inc. (NASDAQ: PMCB) is a clinical-stage biopharmaceutical company focused on the development of cell-based therapies for the treatment of various cancers. The company’s core technology revolves around the encapsulation of live cells within proprietary biocompatible polymers, enabling localized delivery of therapeutic agents directly to tumor sites. This approach is designed to maximize anti-tumor activity while minimizing systemic side effects commonly associated with conventional chemotherapy.

Within its pipeline, Nuvilex is developing multiple lead candidates aimed at solid tumors that are historically difficult to treat. The company’s flagship product candidate utilizes encapsulated live cells to convert an administered prodrug into an active chemotherapy agent in situ, offering a novel mechanism to target pancreatic, liver and ovarian tumors. Preclinical studies have demonstrated promising safety and efficacy profiles, and the firm is preparing for upcoming clinical trials in collaboration with academic medical centers.

Founded in 2000 under the name Biovax, Inc., the company rebranded as Nuvilex in 2017 to reflect its emphasis on next-generation oncology platforms. Headquartered in Philadelphia, Pennsylvania, Nuvilex operates research and manufacturing facilities in the United States while engaging in strategic partnerships across Europe and Asia to expand clinical development and regulatory support. These alliances enable the company to leverage international expertise in cell therapy manufacturing and to pursue global trial sites.

Nuvilex’s management team combines seasoned executives from the biopharmaceutical and biotechnology sectors. The company’s board and leadership group bring extensive experience in drug development, regulatory affairs and corporate governance. Under their direction, Nuvilex continues to advance its encapsulation technology through IND-enabling studies, with the goal of delivering differentiated cancer therapies to patients facing high-unmet medical needs.